Levosimendan in Europe and China: An Appraisal of Evidence and Context

Levosimendan in Europe and China: An Appraisal of Evidence and Context

The calcium sensitiser levosimendan (SIMDAX; Orion Pharma) has been in clinical use for the management of acute heart failure and a range of related syndromes in many countries around the world for two decades. More recently, levosimendan has become available in China. The authors have examined the...

Full description

Saved in:
Bibliographic Details
Main Authors: Xiangqing Kong, Xinqun Hu, Baotong Hua, Francesco Fedele, Dimitrios Farmakis, Piero Pollesello
Format: Article
Language:English
Published: Radcliffe Medical Media 2021-11-01
Series:European Cardiology Review
Online Access:https://www.ecrjournal.com/articleindex/ecr.2021.41
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items